AI1 min read
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
By OpenSmartRoute editorial · attributed excerpt
From TechCrunch AI
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read the original at TechCrunch AI: Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Keep reading
AI1 min read
Buy one pass to TechCrunch Disrupt 2026 and get 50% off a second of the same ticket type. Register before event starts on October 13 at 8 a.m. PT.
AI1 min read
Prism's larger goal is open-weight AI that runs on devices and makes better use of the computing power they already have.
AI1 min read
BottleCap AI has released ThinkingCap-Qwen3.8-27B, a fine-tune of Qwen3.8-27B that spends 37.2% fewer thinking tokens across 12 benchmarks. Macro accuracy moves from 86.65% to 85.79%, and long-context AA-LCR improves by 2.25pp. The model...
